作者
Patrick Mismetti, Silvy Laporte, Olivier Pellerin, Pierre-Vladimir Ennezat, Francis Couturaud, Antoine Elias, Nicolas Falvo, Nicolas Meneveau, Isabelle Quere, Pierre-Marie Roy, Olivier Sanchez, Jeannot Schmidt, Christophe Seinturier, Marie-Antoinette Sevestre, Jean-Paul Beregi, Bernard Tardy, Philippe Lacroix, Emilie Presles, Alain Leizorovicz, Hervé Decousus, Fabrice-Guy Barral, Guy Meyer, PREPIC2 Study Group
发表日期
2015/4/28
期刊
Jama
卷号
313
期号
16
页码范围
1627-1635
出版商
American Medical Association
简介
Importance
Although retrievable inferior vena cava filters are frequently used in addition to anticoagulation in patients with acute venous thromboembolism, their benefit-risk ratio is unclear.
Objective
To evaluate the efficacy and safety of retrievable vena cava filters plus anticoagulation vs anticoagulation alone for preventing pulmonary embolism recurrence in patients presenting with acute pulmonary embolism and a high risk of recurrence.
Design, Setting, and Participants
Randomized, open-label, blinded end point trial (PREPIC2) with 6-month follow-up conducted from August 2006 to January 2013. Hospitalized patients with acute, symptomatic pulmonary embolism associated with lower-limb vein thrombosis and at least 1 criterion for severity were assigned to retrievable inferior vena cava filter implantation plus anticoagulation (filter group; n = 200) or anticoagulation alone with no filter implantation (control …
学术搜索中的文章
P Mismetti, S Laporte, O Pellerin, PV Ennezat… - Jama, 2015